{"id":"nimorazole","rwe":[{"pmid":"41138857","year":"2026","title":"An international placebo-controlled randomized multicenter trial of nimorazole with accelerated chemo-radiotherapy for locally advanced HPV-negative squamous cell carcinoma of the head and neck (HNSCC).","finding":"","journal":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","studyType":"Clinical Study"},{"pmid":"40987385","year":"2025","title":"Radiotherapy quality assurance of the prospective randomised EORTC-1219/DAHANCA-29 trial: an individual case review analysis.","finding":"","journal":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","studyType":"Clinical Study"},{"pmid":"40965329","year":"2025","title":"Impact of GTV-CTV margin and other predictors on radiation-induced dysphagia in head and neck cancer patients from DAHANCA group.","finding":"","journal":"Acta oncologica (Stockholm, Sweden)","studyType":"Clinical Study"},{"pmid":"40746124","year":"2025","title":"[A case of toxic encephaloneuropathy during treatment with nimorazole].","finding":"","journal":"Ugeskrift for laeger","studyType":"Clinical Study"},{"pmid":"40258418","year":"2025","title":"DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck.","finding":"","journal":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","studyType":"Clinical Study"}],"tags":[{"label":"nimorazole","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"P01AB06","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antiparasitic Agents","category":"pharmacology"},{"label":"Antiprotozoal Agents","category":"pharmacology"},{"label":"Antitrichomonal Agents","category":"pharmacology"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"naxofem","offLabel":[],"synonyms":["nimorazole","naxofem","naxogin","nimorazol","nitrimidazine","nulogyl"],"timeline":[],"approvals":[],"brandName":"Naxofem","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"nimorazole","explanation":"Imagine your body's cells are like a factory, and DNA synthesis is the process of making new parts. Nimorazole blocks the machine that makes these parts, which can help stop cancer cells from growing and dividing.","oneSentence":"Nimorazole is thought to work by inhibiting the enzyme responsible for DNA synthesis, thereby preventing the growth of cancer cells.","technicalDetail":"Nimorazole is a thiosemicarbazone compound that acts as a DNA synthesis inhibitor, likely targeting the enzyme ribonucleotide reductase."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1938","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NIMORAZOLE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NIMORAZOLE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:09:10.149267","biosimilars":[],"competitors":[{"drugName":"metronidazole","drugSlug":"metronidazole","fdaApproval":"1963-07-18","patentExpiry":"Oct 4, 2039","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tinidazole","drugSlug":"tinidazole","fdaApproval":"2004-05-17","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"secnidazole","drugSlug":"secnidazole","fdaApproval":"2017-09-15","patentExpiry":"Sep 4, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"furazolidone","drugSlug":"furazolidone","fdaApproval":"1958-01-20","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"nimorazole","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"metronidazole","brandName":"metronidazole","genericName":"metronidazole","approvalYear":"1963","relationship":"same-class"},{"drugId":"tinidazole","brandName":"tinidazole","genericName":"tinidazole","approvalYear":"2004","relationship":"same-class"},{"drugId":"secnidazole","brandName":"secnidazole","genericName":"secnidazole","approvalYear":"2017","relationship":"same-class"},{"drugId":"furazolidone","brandName":"furazolidone","genericName":"furazolidone","approvalYear":"1958","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04124198","phase":"NA","title":"Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Christian von Buchwald","startDate":"2019-03-01","conditions":["Oropharynx Cancer","Oropharynx Squamous Cell Carcinoma","Carcinoma, Squamous Cell","Carcinoma","Oropharyngeal Neoplasms","Neoplasms, Squamous Cell","Neoplasms, Glandular and Epithelial","Neoplasms by Histologic Type","Pharyngeal Neoplasms Malignant and Unspecified","Otorhinolaryngologic Neoplasms","Head and Neck Neoplasms","Neoplasms by Site","Otorhinolaryngologic Diseases","Pharyngeal Diseases","Papillomavirus Infections","Virus Diseases","DNA Virus Infections","Tumor Virus Infections","Quality of Life"],"enrollment":138,"completionDate":"2029-12"},{"nctId":"NCT05423704","phase":"NA","title":"Feasibility of Patient Selection and Treatment of Head-neck Cancer With Proton Therapy in Denmark","status":"ACTIVE_NOT_RECRUITING","sponsor":"Danish Head and Neck Cancer Group","startDate":"2019-05-20","conditions":["Head-and-neck Cancer"],"enrollment":63,"completionDate":"2026-05-14"},{"nctId":"NCT01880359","phase":"PHASE3","title":"AF CRT +/- Nimorazole in HNSCC","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2014-07-25","conditions":["Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers"],"enrollment":640,"completionDate":"2023-01-09"},{"nctId":"NCT01950689","phase":"PHASE3","title":"NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)","status":"COMPLETED","sponsor":"The Christie NHS Foundation Trust","startDate":"2014-09-11","conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":338,"completionDate":"2021-01-07"},{"nctId":"NCT02661152","phase":"PHASE3","title":"DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.","status":"UNKNOWN","sponsor":"Danish Head and Neck Cancer Group","startDate":"2016-09","conditions":["Head and Neck Squamous Cell Carcinoma","Radiotherapy","Hypoxic Modification","Hypoxia","Gene Profile, Gene Signature"],"enrollment":1252,"completionDate":"2023-12"},{"nctId":"NCT04607694","phase":"NA","title":"DAHANCA 35: Proton Versus Photon Therapy for Head-neck Cancer","status":"UNKNOWN","sponsor":"Danish Head and Neck Cancer Group","startDate":"2020-10-09","conditions":["Head-and-neck Cancer"],"enrollment":600,"completionDate":"2025-09"},{"nctId":"NCT02976051","phase":"PHASE2","title":"DAHANCA 33: Image Guided Dose-escalated Radiotherapy to Patients With Hypoxic HNSCC","status":"UNKNOWN","sponsor":"Danish Head and Neck Cancer Group","startDate":"2017-01","conditions":["Locally Advanced Head and Neck Cancer","Radiotherapy","Hypoxic Radioresistance"],"enrollment":60,"completionDate":"2022-12"},{"nctId":"NCT03981068","phase":"NA","title":"DAHANCA 37. Re-irradiation With Proton Radiotherapy","status":"UNKNOWN","sponsor":"Danish Head and Neck Cancer Group","startDate":"2019-09-01","conditions":["Head and Neck Neoplasms"],"enrollment":20,"completionDate":"2025-08-30"},{"nctId":"NCT01733823","phase":"PHASE1,PHASE2","title":"DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole","status":"COMPLETED","sponsor":"Danish Head and Neck Cancer Group","startDate":"2013-01","conditions":["HNSCC,Larynx, Pharynx and Oral Cavity"],"enrollment":31,"completionDate":"2016-03"},{"nctId":"NCT01507467","phase":"PHASE3","title":"IAEA-HypoX. Accelerated Radiotherapy With or Without Nimorazole in Squamous Cell Carcinoma of the Head and Neck","status":"TERMINATED","sponsor":"Danish Head and Neck Cancer Group","startDate":"2012-03","conditions":["Head and Neck Carcinoma"],"enrollment":104,"completionDate":"2016-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000167080","NDDF":"004011","UNII":"469ULX0H4G","CHEBI":"CHEBI:134929","INN_ID":"2736","RXNORM":"7427","UMLSCUI":"C0028095","ChEMBL_ID":"CHEMBL435966","KEGG_DRUG":"D07352","DRUGBANK_ID":"DB12172","PUBCHEM_CID":"23009","SNOMEDCT_US":"324945001","MESH_DESCRIPTOR_UI":"D009554"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":139,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"P01AB06","allCodes":["P01AB06"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jan","pmid":"41138857","title":"An international placebo-controlled randomized multicenter trial of nimorazole with accelerated chemo-radiotherapy for locally advanced HPV-negative squamous cell carcinoma of the head and neck (HNSCC).","journal":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology"},{"date":"2025 Dec","pmid":"40987385","title":"Radiotherapy quality assurance of the prospective randomised EORTC-1219/DAHANCA-29 trial: an individual case review analysis.","journal":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology"},{"date":"2025 Sep 18","pmid":"40965329","title":"Impact of GTV-CTV margin and other predictors on radiation-induced dysphagia in head and neck cancer patients from DAHANCA group.","journal":"Acta oncologica (Stockholm, Sweden)"},{"date":"2025 Jul 14","pmid":"40746124","title":"[A case of toxic encephaloneuropathy during treatment with nimorazole].","journal":"Ugeskrift for laeger"},{"date":"2025 Jul","pmid":"40258418","title":"DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck.","journal":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Naxofem, also known as Naxogin, is a small molecule. It has synonyms including Naxogin 500, Nimorazol, Nimorazole, and Nimorazole.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}